Lipids & metabolic liver disease
Cost‐Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in the United States
Authors' conclusion
At current U.S. prices, tirzepatide and semaglutide are cost-effective for MASH with F2-F3 fibrosis, while resmetirom is not.
Study context
- Population
- Simulated U.S. adults with biopsy-confirmed MASH and F2-F3 fibrosissimulated cohort
- Exposure
- Resmetirom, semaglutide and tirzepatide, each vs standard of care
- Outcome
- Incremental cost-effectiveness ratio vs standard of care ($/QALY)
- Follow-up
- Lifetime horizon
Methodological detailsMarkov cohort model, lifetime horizon, U.S. healthcare payer perspective, efficacy inputs from Bayesian network meta-analysis, each therapy vs standard of care; no sequential incremental analysis, $100 000/QALY willingness-to-pay threshold
- Markov cohort model
- Lifetime horizon
- U.S. healthcare payer perspective
- Efficacy inputs from Bayesian network meta-analysis
- Each therapy vs standard of care; no sequential incremental analysis
- $100 000/QALY willingness-to-pay threshold
Main finding
As reported in the abstract
ICER vs standard of care (base case)
Tirzepatide
$42 705/QALY
Semaglutide
$80 076/QALY
Resmetirom
$273 445/QALY
Observational data: associations, not effects.
Further findings
| Outcome | Tirzepatide | Semaglutide |
|---|---|---|
| Probability of cost-effectiveness at $100 000/QALY (probabilistic sensitivity analysis) | 99.5% | 89.8% |
Probability of cost-effectiveness at $100 000/QALY (probabilistic sensitivity analysis)
- Drug price was the most influential parameter in sensitivity analyses
Original publication
Cost‐Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in the United States. Diabetes Obes Metab. Published 25 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →